Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Purpose: For primary melanomas, tumor thickness, mitotic rate, and ulceration are well-laid cornerstones of prognostication. However, a molecular exposition of melanoma aggressiveness is critically missing. We recently uncovered a four-class structure in metastatic melanoma, which predicts outcome and informs biology. This raises the possibility that a molecular structure exists even in the early stages of melanoma and that molecular determinants could underlie histophenotype and eventual patient outcome. Experimental Design: We subjected 223 archival primary melanomas to a horizontally integrated analysis of RNA expression, oncogenic mutations at 238 lesions, histomorphometry, and survival data. Results: Our previously described four-class structure that was elucidated in metastatic lesions was evident within the expression space of primary melanomas. Because these subclasses converged into two larger prognostic and phenotypic groups, we used the metastatic lesions to develop a binary subtype-based signature capable of distinguishing between “high” and “low” grade forms of the disease. The two-grade signature was subsequently applied to the primary melanomas. Compared with low-grade tumors, high-grade primary melanomas were significantly associated with increased tumor thickness, mitotic rate, ulceration (all P < 0.01), and poorer relapse-free (HR = 4.94; 95% CI, 2.84–8.59), and overall (HR = 3.66; 95% CI, 2.40–5.58) survival. High-grade melanomas exhibited elevated levels of proliferation and BRCA1/DNA damage signaling genes, whereas low-grade lesions harbored higher expression of immune genes. Importantly, the molecular-grade signature was validated in two external gene expression data sets. Conclusions: We provide evidence for a molecular organization within melanomas, which is preserved across all stages of disease. Clin Cancer Res; 18(15); 4026–36. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While several studies found an association between DNA damage response gene upregulation and melanoma progression, the upregulated genes did not include NER genes64,65.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548 · cited 1×
“Both genes have also been shown to be amplified or upregulated in melanoma (16, 17) and may play significant roles in melanoma mitogenicity along with other species revealed by these signatures.”
Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
Clark, W. H., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M., & Halpern, A. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1893 · Cited by 1,247
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, T. M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4327 · Cited by 1,042
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., Kester, M., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 594
Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome
Winnepenninckx, V., Lazar, V., Michiels, S., Dessen, P., Stas, M., Alonso, S. R., Avril, M.-F., Ortiz Romero, P. L., Robert, T., Balacescu, O., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj103 · Cited by 480
Bogunovic, D., O'Neill, D. W., Belitskaya-Levy, I., Vacic, V., Yu, Y.-L., Adams, S., Darvishian, F., Berman, R., Shapiro, R., Pavlick, A. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905139106 · Cited by 384
Thompson, J. F., Soong, S.-J., Balch, C. M., Gershenwald, J. E., Ding, S., Coit, D. G., Flaherty, K. T., Gimotty, P. A., Johnson, T., Johnson, M. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5812 · Cited by 363
Cited by
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
Self-citationLauss, M., Donia, M., Harbst, K., Andersen, R., Mitra, S., Rosengren, F., Salim, M., Vallon-Christersson, J., Törngren, T., Kvist, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01460-0 · Cited by 470
Self-citationPhenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
Mechanisms and prevention of UV‐induced melanoma
Sample, A., & He, Y. (2018) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/phpp.12329 · Cited by 372
Gerami, P., Cook, R. W., Wilkinson, J., Russell, M. C., Dhillon, N., Amaria, R. N., Gonzalez, R., Lyle, S., Johnson, C. E., Oelschlager, K. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3316 · Cited by 278
Metadata
- Authors
- Harbst, K., Staaf, J., Lauss, M., Karlsson, A., Måsbäck, A., Johansson, I., Bendahl, P.-O., Vallon-Christersson, J., Törngren, T., Ekedahl, H., Geisler, J., Höglund, M., Ringnér, M., Lundgren, L., Jirström, K., Olsson, H., Ingvar, C., Borg, Å., Tsao, H., & Jönsson, G.
- Affiliations
- Harvard University (US)
- Authors' Affiliations: 1Department of Oncology, Clinical Sciences; 2CREATE Health Strategic Center for Clinical Cancer Research, Departments of 3Pathology and 4Surgery, Lund University, Lund, Sweden; 5Department of Oncology, Akershus University Hospital, University of Oslo, Norway; 6Department of Dermatology, Harvard Medical School; and 7Wellman Center for Photomedicine, MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts
- Corresponding author
- Tsao, Hensin
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2012-07-30
- Volume
- 18
- Issue
- 15
- Pages
- 4026-4036
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3467105
- OpenAlex
- W2149635248
- Cited by
- 105
- References
- 22
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 4 · 2022: 2 · 2021: 7 · 2020: 7 · 2019: 10 · 2018: 12 · 2017: 11 · 2016: 7 · 2015: 17 · 2014: 16 · 2013: 5 · 2012: 1
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Cancer Institute (K24CA149202, P50CA093683)
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- primary melanoma, molecular subtypes, tumor grade, prognostic signature, metastatic melanoma, histomorphometry, tumor thickness, mitotic activity, ulceration, immune-related genes, proliferation genes, relapse-free survival, overall survival, gene expression profiling
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Gene Expression Regulation, Neoplastic, BRCA1 Protein, Gene Expression Profiling, Kaplan-Meier Estimate, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-0343
- The paper
- Harbst, K., Staaf, J., Lauss, M., Karlsson, A., Måsbäck, A., Johansson, I., Bendahl, P.-O., Vallon-Christersson, J., Törngren, T., Ekedahl, H., Geisler, J., Höglund, M., Ringnér, M., Lundgren, L., Jirström, K., Olsson, H., Ingvar, C., Borg, Å., Tsao, H., & Jönsson, G. (2012). Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-0343
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.